Evidence map›Paper›PMID 39431379›Full record

SynthesisDiabetes, obesity & metabolism2025

Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.

Ruoyang Jiao, Chu Lin, Xiaoling Cai, Jingxuan Wang, Yuan Wang, Fang Lv, Wenjia Yang, Linong Ji

Registry-linked trialAbstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07713992 (Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide), which is not on this map. Cited by 31 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07713992 nanot yet recruitingstarted 2026, after this paper: background citation

Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)

Ran2026Enrolled72Registered outcomes20Posted comparisons0ConditionsNonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus, Type 2 Diabetes Mellitus (T2DM)ArmsMazdutide(Dual GLP-1R/GCGR Agonist), Semaglutide (1 Mg Dose)
PMID 23999198PMID 35013484PMID 18726585PMID 33880754PMID 34310013PMID 40802944PMID 40491239PMID 39809974PMID 34713962PMID 20957001PMID 28733905PMID 29221645other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Pooled it
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Muscle health in the modern era of incretin-based therapies.European journal of clinical investigation · 2026
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruoyang Jiao *Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Chu Lin *Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.ORCID 0000-0002-2365-9831
Xiaoling CaiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.ORCID 0000-0002-7881-0543
Jingxuan WangDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Yuan WangDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Fang LvDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Wenjia YangDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.ORCID 0000-0003-0610-5121
Linong JiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.ORCID 0000-0002-3262-2168

Funding

National Natural Science Foundation of China 81970698National Natural Science Foundation of China 81970708Natural Science Foundation of Beijing Municipality 7202216
6 · The paper itself

Abstract

aimDiabetes is an independent risk factor for muscle mass loss, with possible mechanisms including impaired insulin signalling and chronic inflammation. The use of a glucagon-like peptide 1 (GLP-1) receptor-based agonist could lead to weight reduction, which might result from the loss of both fat and skeletal muscle. However, the body composition-modifying effects of GLP-1 receptor-based agonists have not been systematically characterized.

methodsPubMed, EMBASE, the Cochrane Center Register of Controlled Trials for Studies and Clinicaltrial.gov were searched from inception to October 2023. Randomized controlled trials of GLP-1 receptor agonist or glucose-dependent insulinotropic polypeptide/GLP-1 receptor dual agonist, which reported the changes of body composition, were included. The results were computed as weighted mean differences (WMDs) and 95% confidence intervals (CIs) in a random-effects model.

resultsIn all, 19 randomized controlled trials were included. When compared with controls, substantial reductions in fat body mass were observed in patients using GLP-1 receptor-based agonist treatment (WMD = -2.25 kg, 95% CI -3.40 to -1.10 kg), with decrease in areas of both subcutaneous fat (WMD = -38.35 cm

conclusionCompared with the controls, GLP-1 receptor-based agonist users experienced greater reductions in fat body mass, with body shaping effects in terms of both subcutaneous fat mass and visceral fat mass. Although greater reductions in lean body mass were also observed in GLP-1 receptor-based agonist users, the changes in lean mass percentage were comparable between the users and non-users.

Indexed as

Body CompositionDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsRandomized Controlled Trials as TopicFemaleHumansMaleWeight LossGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agentsfat massglucagon‐like peptide 1lean masssarcopeniatype 2 diabetes

Identifiers

PMID39431379

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.